From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines
Genetic Engineering & Biotechnology News
Nov 15, 2022
Media
News Archive
The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs
Endpoints News
Nov 15, 2022
Media
Roche-backed Bonum bags $93M series A to develop new class of conditionally active therapies
Fierce Biotech
Nov 15, 2022
Media
Good Therapeutics’ Offshoot Bonum Launches with $93 Million in Series A (Updated)
BioSpace
Nov 15, 2022
Media
Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies
“We believe that this technology has broad potential and we are excited to apply it in new areas…”
Healthcare Investor Digitalis Ventures Nets $300 Million Fund
Wall Street Journal
Oct 18, 2022
Media